TITLE

Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting

AUTHOR(S)
Van Rossum, Inge; Tenback, Diederik; Os, Jim van
PUB. DATE
January 2009
SOURCE
BMC Psychiatry;2009, Vol. 9, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: It has been suggested that dopamine dysfunction may play a role in bipolar disorder (BD). An indirect approach to examine this issue was developed, focusing on associations between dopamine proxy measures observed in BD (dopamine-related clinical traits using tardive movement syndromes as dopamine proxy measure of reference). Methods: 3459 eligible bipolar patients were enrolled in an observational study. Incidence rates of tardive movement syndromes (tardive dyskinesia and tardive dystonia; TDD) were examined. A priori hypothesized associations between incident TDD and other dopamine proxies (e.g. prolactin-related adverse effects, bipolar symptoms) were tested over a 2 year follow-up period. Results: The incidence rate of tardive syndromes was 4.1 %. Incident TDD was independently associated not only with use of antipsychotics, but also with more severe bipolar symptoms, other extrapyramidal symptoms and prolactin-related adverse effects of medication. Conclusion: Apart from the well-known association with antipsychotics, development of TDD was associated with various other dopamine proxy measures, indirectly supporting the notion of generalised dopamine dysregulation in BD.
ACCESSION #
42408644

 

Related Articles

  • Efficacy of Low-dose Pramipexole Augmentation in the Treatment of Refractory Psychotic Depression Complicated with Tardive Dyskinesia: A Case Report. Erkan, Arzu; Pirildar, Sebnem; Acarer, Ahmet; Akdeniz, Fisun // Klinik Psikofarmakoloji Bulteni;Dec2011, Vol. 21 Issue 4, p353 

    Tardive dyskinesia (TD) is a severe complication of antipsychotic treatment. Pramipexole can be effective in the treatment of TD due to its D3 dopamine receptor agonist effect. Studies conducted in bipolar depression and treatment-resistant depression (TRD), support the antidepressant effect of...

  • Management of bipolar I depression: clinical utility of lurasidone. Findlay, Lillian Jan; El-Mallakh, Peggy; El-Mallakh, Rif S. // Therapeutics & Clinical Risk Management;2015, Vol. 11, p75 

    Lurasidone is a benzisothiazol derivative second-generation antipsychotic. It has been approved in the United States and Europe for treatment of acute schizophrenia and bipolar depression. In type I bipolar subjects, treatment with lurasidone monotherapy of adjunctive therapy to lithium or...

  • Lithium.  // Reactions Weekly;5/11/2013, Issue 1452, p28 

    The article presents a case study of a 68-year-old man with a history in bipolar disorder, who developed orolingual dyskinesia related to lithium intoxication.

  • A Case of Persistent Tardive Dyskinesia in Bipolar Mania. Ong Kheng Yee // Journal of Mood Disorders;2013, Vol. 3 Issue 3, p128 

    Mr. CK, a 40-year-old Chinese gentleman is a Bipolar I Disorder patient with no history of depressive episodes. He had never achieved full remission and had 3 previous admissions for manic episodes due to poor insight to his illness. Patient experienced his first manifestation of unexpected...

  • Ser9Gly dopamine D3 receptor polymorphism and spontaneous dyskinesia in never-medicated schizophrenic patients. Løvlie, R.; Thara, R.; Padmavathi, R.; Steen, V.M.; McCreadie, R.G. // Molecular Psychiatry;2001, Vol. 6 Issue 1, p6 

    Discusses a study which demonstrated an association between homozyosity for the Gly-9 variant of the dopamine D3 receptor and the presence of the Tardive dyskinesia (TD) in neuroleptic-treated schizophrenic patients. Background on TD; Risk factors for the development of TD; Genetic...

  • Metoclopramide and tardive dyskinesia in the elderly. Orme, M.L.'E.; Tallis, R.C. // British Medical Journal (Clinical Research Edition);8/18/1984, Vol. 289 Issue 6442, p397 

    Examines the association of tardive dyskinesia with metoclopramide treatment among the elderly patients. Clinical manifestations of the disorder; Incidence of several extrapyramidal complications in patients; Medical intervention for the disorder.

  • General Summary. Midei, A.; Licinio, J. // Molecular Psychiatry;Oct2004, Vol. 9 Issue 10, p893 

    Presents several abstracts related to psychiatry. "Analysis of the Novel TPJ2 Gene in Bipolar Disorder and Suicidality," by V De Luca, DJ Mueller, S Tharmlingam, N King, JL Kennedy; "Glial Cell Dysfunction in Schizophrenia Indicated by Increased S100B in the CSF," by M Rothermundt, P Falkai, and...

  • Trihexyphenidyl Triggered Hypomania in a Bipolar Patient. Yıldızhan, Eren; Batmaz, Serap; Karagöz Sakallı, Nazan; Kurt, Erhan // Journal of Mood Disorders;Jun2012, Vol. 2 Issue 2, p77 

    We observed a case of tardive dyskinesia after regular use of low dose chlorpromazine. An anticholinergic agent; trihexyphenidyl (THX) was prescribed to treat the tardive dyskinesia. The treatment response was satisfactory, but brief hypomanic episodes occurred. Because the patient was symptom...

  • Benzatropine/olanzapine.  // Reactions Weekly;7/5/2008, Issue 1209, p11 

    The article describes the case of a 51-year-old woman who developed tardive dyskinesia during treatment with olanzapine and benzatropine. Suffering from bipolar disorder, the woman started receiving olanzapine everyday for a period of 8 months. She also received benzatropine as a potential...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics